Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations

HIGHLIGHTS

• who: Daniel R. Principe from the University of have published the paper: Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations, in the Journal: Scientific Reports Scientific Reports
• what: The authors evaluated genomic data from a large pan-cancer cohort initially used to support the predictive value of TMB in patients receiving ICI-based immunotherapy.
• how: Categorical data were evaluated using the Pearson's chi-squared test. For time-to-endpoint/survival analyses data were analyzed using the Kaplan Meier method/log rank test with hazard . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.